access to medicines

Printer-friendly version
New review rules—the impact on drug access in Canada

In 2017, the federal government introduced new regulations for the drug review board.

Printer-friendly version
Minister of health makes dubious claims about Ottawa’s pharmacare plan

More regulation will likely lead to slower and more limited access to drugs.

Printer-friendly version
National pharmacare can hurt patients more than it helps

Canadians can also expect tax hikes to pay for the government drug program.

Printer-friendly version
Canada's free ride on U.S. drug development may end soon

In a bid to get even steeper drug discounts, Health Canada recently proposed changes to our reference-pricing system.

Printer-friendly version
Increasing barriers for drug manufacturers may ultimately hurt patients

Ottawa’s changes may delay the launch of new innovative medications in Canada.

Printer-friendly version
Queen's Park should amend existing programs to better target vulnerable groups.